Clinical bottom line
Chronic pruritic dermatitis in patients with chronic kidney disease (CKD) remains a challenging condition with limited effective systemic treatment options. Recent evidence highlights the potential of novel systemic therapies, including κ-opioid receptor agonists, to alleviate uremic pruritus with acceptable safety profiles. However, data on broader systemic treatments for chronic pruritic dermatitis in CKD populations, especially beyond uremic pruritus, are sparse and largely anecdotal. Clinicians should consider emerging therapies cautiously, balancing symptom relief against the complex comorbidities and altered pharmacokinetics in CKD patients.
What the evidence shows
Pruritus is a common and distressing symptom in CKD, particularly in patients on dialysis, often manifesting as chronic pruritic dermatitis with significant impact on quality of life (Cîrstea et al., 2025). The pathophysiology involves multifactorial mechanisms including systemic inflammation, dysregulated opioid pathways, and skin barrier dysfunction.
A notable systemic treatment approach involves κ-opioid receptor agonists, which target dysregulated opioid signaling implicated in uremic pruritus. Kumagai et al. (2012) demonstrated that a novel κ-agonist significantly reduced pruritus intensity in dialysis patients with an acceptable safety profile, suggesting a promising therapeutic avenue for intractable pruritus in CKD.
Beyond uremic pruritus, systemic immunomodulatory therapies have been reported anecdotally. Fang et al. (2026) described successful treatment of new-onset plaque psoriasis with secukinumab, an IL-17A inhibitor, in a peritoneal dialysis patient, indicating that biologics may be feasible in select CKD patients with inflammatory dermatoses. However, this is a single case report and cannot be generalized without further study.
Overall, systemic treatments must be carefully selected due to altered drug metabolism and increased risk of adverse events in CKD. The evidence base remains limited, with most data derived from small studies or case reports rather than large randomized controlled trials.
Caveats and uncertainty
The evidence for systemic treatments of chronic pruritic dermatitis in CKD is limited by small sample sizes, heterogeneous patient populations, and lack of long-term safety data. The κ-opioid receptor agonist studies primarily focus on uremic pruritus in dialysis patients and may not extrapolate to all forms of chronic pruritic dermatitis in CKD.
Immunomodulatory biologics, while promising in isolated cases, carry risks of infection and altered pharmacodynamics in CKD that require cautious use and further validation. The complex comorbidity burden in CKD, including cardiovascular disease and systemic calcification, complicates treatment decisions (McCullough et al., 2008).
Additionally, the interplay between CKD progression and skin manifestations is incompletely understood, and systemic therapies may have variable efficacy depending on CKD stage and dialysis modality.
How this may change practice
Clinicians managing chronic pruritic dermatitis in CKD should remain aware of emerging systemic options such as κ-opioid receptor agonists that specifically target uremic pruritus mechanisms. These agents may offer symptom relief where conventional therapies fail, particularly in dialysis patients.
For inflammatory dermatoses like psoriasis occurring in CKD, biologics may be considered on a case-by-case basis with close monitoring, although robust evidence is lacking. Multidisciplinary collaboration with nephrology is essential to optimize treatment safety and efficacy.
Future integration of novel systemic treatments should be guided by ongoing research and tailored to individual patient risk profiles, with attention to altered pharmacokinetics and comorbidities inherent in CKD.